Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 9/20 | 0.49 |
| ▸ | EPAS1 | Q99814 | 15/20 | 0.46 |
| ▸ | ARNT | P27540 | 5/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18067969 | 1.00 | VEGFA (0.49) | VEGFAEPAS1ARNTCYP2C9CYP2C19 | |
| SCHEMBL18163795 | 0.87 | EPAS1 (0.52) | VEGFAEPAS1 | |
| SCHEMBL21080634 | 0.87 | EPAS1 (0.52) | VEGFAEPAS1 | |
| SCHEMBL18067967 | 0.87 | EPAS1 (0.52) | VEGFAEPAS1 | |
| SCHEMBL19870708 | 0.87 | EPAS1 (0.52) | VEGFAEPAS1 | |
| SCHEMBL19858582 | 0.87 | EPAS1 (0.52) | VEGFAEPAS1 | |
| SCHEMBL19858573 | 0.76 | ARNT (0.31) | EPAS1ARNT | |
| SCHEMBL20315393 | 0.74 | VEGFA (0.62) | VEGFAEPAS1ARNTCYP2C9CYP2C19 | |
| SCHEMBL19870698 | 0.74 | VEGFA (0.58) | VEGFAEPAS1ARNTCYP2C9CYP2C19 | |
| SCHEMBL22473050 | 0.73 | EPAS1 (0.38) | VEGFAEPAS1ARNT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180177754-A1 | COMPOSITIONS FOR USE IN TREATING PULMONARY ARTERIAL HYPERTENSION | PELOTON THERAPEUTICS, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180162807-A1 | AROMATIC COMPOUNDS AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2018-06-14 | — | — | US | disclosed |
| US-20180140569-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180042884-A1 | COMPOSITIONS FOR USE IN TREATING GLIOBLASTOMA | PELOTON THERAPEUTICS, INC. | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180042884-A1 | COMPOSITIONS FOR USE IN TREATING GLIOBLASTOMA | MGMT, NEFM, TUBB3 | VEGFA 189/4885EPAS1 2505/4885ARNT 4465/4885 |
| US-20180140569-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | HIF1AN, HIF1A, EGLN2 | VEGFA 89/4885EPAS1 15/4885ARNT 22/4885 |
| US-20180177754-A1 | COMPOSITIONS FOR USE IN TREATING PULMONARY ARTERIAL HYPERTENSION | MYLK, TNNI3, PDE2A | VEGFA 34/4885EPAS1 450/4885ARNT 3089/4885 |
| US-20180162807-A1 | AROMATIC COMPOUNDS AND USES THEREOF | HIF1A, HIF1AN, VHL | VEGFA 419/4885EPAS1 13/4885ARNT 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.